Cited by

• Effects of mianserin in neuroleptic-induced parkinsonism.

  Korsgaard S, Friis T. Korsgaard S, et al. Psychopharmacology (Berl). 1986;88(1):109-11. doi: 10.1007/BF00310523. Psychopharmacology (Berl). 1986. PMID: 2868480 Clinical Trial.
• Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic.

  Feldman M, Marmol S, Margolesky J. Feldman M, et al. Ther Clin Risk Manag. 2022 Dec 20;18:1129-1142. doi: 10.2147/TCRM.S360268. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 36573102 Free PMC article. Review.
• Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.

  Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, Gastaldon C, Papola D, Purgato M, Nosari G, Del Giovane C, Correll CU, Barbui C. Ostuzzi G, et al. World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972. World Psychiatry. 2022. PMID: 35524620 Free PMC article.
• The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

  Bench CJ, Lammertsma AA, Grasby PM, Dolan RJ, Warrington SJ, Boyce M, Gunn KP, Brannick LY, Frackowiak RS. Bench CJ, et al. Psychopharmacology (Berl). 1996 Mar;124(1-2):141-7. doi: 10.1007/BF02245614. Psychopharmacology (Berl). 1996. PMID: 8935809 Clinical Trial.
• Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials.

  Bogers JPAM, Hambarian G, Walburgh Schmidt N, Vermeulen JM, de Haan L. Bogers JPAM, et al. Schizophr Bull. 2023 Jan 3;49(1):11-23. doi: 10.1093/schbul/sbac138. Schizophr Bull. 2023. PMID: 36200866 Free PMC article.